Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

by Hofheinz, R.-D., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., Hacker, U. T.
Published 2016

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours

by Coutelle, O, Schiffmann, L M, Liwschitz, M, Brunold, M, Goede, V, Hallek, M, Kashkar, H, Hacker, U T
Published 2015

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

by Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Published 2013

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

by Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U. T., Köhne, C. H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K. B.
Published 2013